HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunohistochemical Screening of Upper Tract Urothelial Carcinomas for Lynch Syndrome Diagnostics: A Systematic Review.

AbstractOBJECTIVE:
To review the effect of universal screening of newly diagnosed upper tract urothelial carcinomas (UTUC) for mismatch repair (MMR) protein loss to aid in Lynch syndrome diagnostics.
MATERIALS AND METHODS:
Studies were identified through PubMed on December 1, 2021. Eligibility criteria were universal immunohistochemical analyses for at least 2 MMR proteins in unselected, consecutively collected UTUC cohorts. Exclusion criteria included reviews, case-reports, non-English language, and non-humans. Risk of bias was assessed using a modified Newcastle-Ottawa scale. Meta-analyses were performed to compare the association between clinical criteria and Lynch syndrome diagnoses.
RESULTS:
From 12 included studies, 1628 surgically removed UTUC from 1626 patients were screened for MMR protein loss. In 11 studies, 140 of the 1559 patients had tumors with loss (9.0%) with 80.7% showing loss of MSH2, MSH6, or both. In 7 studies, genetic testing confirmed Lynch syndrome diagnosis for 20 of 970 patients (2.1%). In 8 studies, 31 patients were given a clinical Lynch syndrome diagnosis (2.6%). In total, 51 assumed or verified Lynch syndrome patients were identified among 1087 patients (4.7%). Meta-analyses of 3 studies showed significant association between previous cancer diagnosis and Lynch syndrome-associated UTUC (P = .038).
CONCLUSION:
Despite the few studies conducted and lack of genetic testing, current data suggests that universal screening for MMR protein loss in UTUC may result in Lynch syndrome diagnoses in 4.7%. However, for the screening to be effective for Lynch syndrome diagnostics, follow-up investigations, such as genetic testing for MMR variants, are needed.
AuthorsMaria Rasmussen, Mia Gebauer Madsen, Christina Therkildsen
JournalUrology (Urology) Vol. 165 Pg. 44-53 (07 2022) ISSN: 1527-9995 [Electronic] United States
PMID35217028 (Publication Type: Journal Article, Review, Systematic Review, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Chemical References
  • MutL Protein Homolog 1
Topics
  • Carcinoma, Transitional Cell (diagnosis, genetics)
  • Colorectal Neoplasms, Hereditary Nonpolyposis (diagnosis, genetics, pathology)
  • DNA Mismatch Repair
  • Humans
  • Immunohistochemistry
  • MutL Protein Homolog 1 (analysis, genetics)
  • Urinary Bladder Neoplasms

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: